Literature DB >> 33755735

LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI.

Ali Pirasteh1,2,3, E Aleks Sorra4, Hector Marquez4, Robert C Sibley4, Julia R Fielding4, Abhinav Vij4, Nicole E Rich5, Ana Arroyo5, Adam C Yopp6, Gaurav Khatri4, Amit G Singal5, Takeshi Yokoo4.   

Abstract

PURPOSE: To evaluate the inter-reader reproducibility and prognostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (LR-TR) at the time of initial post-treatment evaluation following drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC).
METHODS: This retrospective study included patients with HCC who underwent first-line DEB-TACE between January 2011 and December 2015. Six readers (three fellowship-trained radiologists and three radiology trainees) independently assessed lesion-level response in up to two treated lesions per LR-TR and modified Response Evaluation Criteria in Solid Tumors (mRECIST)-target criteria, as well as patient-level response per mRECIST-overall criteria, on the initial post-treatment CT/MRI. Inter-reader agreement was calculated by Fleiss' multi-reader κ. We tested whether LR-TR, mRECIST-target, and mRECIST-overall response were associated with overall survival using Kaplan-Meier and Cox proportional hazard model analyses.
RESULTS: A total of 82 patients with 113 treated target lesions were included. Inter-reader agreement was moderate for LR-TR and mRECIST-overall (κ range 0.42-0.57), and substantial for mRECIST-target (κ range 0.62-0.66), among all three reader-groups: all readers, experienced readers, and less-experienced readers. LR-TR and mRECIST-target response were not significantly associated with overall survival regardless of reader experience (P > 0.05). In contrast, mRECIST-overall response was significantly associated with overall survival when assessed by all readers (P = 0.02) and experienced readers (P = 0.03), but not by the less-experienced readers (P = 0.35).
CONCLUSION: Although LR-TR algorithm has moderate inter-reader reproducibility, it alone may not predict overall survival on the initial post-treatment CT/MRI after first-line DEB-TACE for HCC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Computed tomography; Hepatocellular carcinoma; Magnetic resonance imaging; Response Evaluation Criteria In Solid Tumors; Therapeutic chemoembolization

Mesh:

Year:  2021        PMID: 33755735     DOI: 10.1007/s00261-021-03043-6

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  22 in total

Review 1.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

2.  The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.

Authors:  Mohammad Chaudhry; Katrina A McGinty; Benjamin Mervak; Reginald Lerebours; Cai Li; Erin Shropshire; James Ronald; Leah Commander; Johann Hertel; Sheng Luo; Mustafa R Bashir; Lauren M B Burke
Journal:  Radiology       Date:  2019-12-17       Impact factor: 11.105

3.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

4.  Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.

Authors:  Riccardo Lencioni; Robert Montal; Ferran Torres; Joong-Won Park; Thomas Decaens; Jean-Luc Raoul; Masatoshi Kudo; Charissa Chang; José Ríos; Valerie Boige; Eric Assenat; Yoon-Koo Kang; Ho-Yeong Lim; Ian Walters; Josep M Llovet
Journal:  J Hepatol       Date:  2017-01-26       Impact factor: 25.083

5.  Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.

Authors:  Adam C Yopp; John C Mansour; Muhammad S Beg; Juan Arenas; Clayton Trimmer; Mark Reddick; Ivan Pedrosa; Gaurav Khatri; Takeshi Yakoo; Jeffrey J Meyer; Jacqueline Shaw; Jorge A Marrero; Amit G Singal
Journal:  Ann Surg Oncol       Date:  2013-12-07       Impact factor: 5.344

6.  Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma.

Authors:  Brian Jin; Dingxin Wang; Robert J Lewandowski; Ahsun Riaz; Robert K Ryu; Kent T Sato; Andrew C Larson; Riad Salem; Reed A Omary
Journal:  AJR Am J Roentgenol       Date:  2011-04       Impact factor: 3.959

7.  Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

Authors:  María Varela; María Isabel Real; Marta Burrel; Alejandro Forner; Margarita Sala; Mercé Brunet; Carmen Ayuso; Lluis Castells; Xavier Montañá; Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2006-11-29       Impact factor: 25.083

Review 8.  The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma.

Authors:  Josep M Llovet; Josep Fuster; Jordi Bruix
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

9.  LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy.

Authors:  Erin L Shropshire; Mohammad Chaudhry; Chad M Miller; Brian C Allen; Erol Bozdogan; Diana M Cardona; Lindsay Y King; Gemini L Janas; Richard K Do; Charles Y Kim; James Ronald; Mustafa R Bashir
Journal:  Radiology       Date:  2019-04-30       Impact factor: 29.146

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.